Skip to main content

Table 1 Clinical efficacy data from LUX-Lung 3

From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

 

Afatinib arm

Pemetrexed-cisplatin arm

Median overall survival, months (95% CI)

28.2 (24.6–33.6)b

28.2 (20.7–33.2)b

Median first-line progression free survival, monthsa

11.1c

6.7c

  1. CI confidence interval
  2. a95%CI was not reported
  3. Source: b Yang et al., [12]; cSequist et al, [6]
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us